(Alliance News) - IQ-AI Ltd said Thursday it is launching a series of new technology initiatives that are expected to form the "backbone" of the company's new products.
The company said these "advancements are substantially derived" from the progress being made with its previously announced Gadolinium free product initiative.
IQ-AI continued: "Most notable of these initiatives is a project which we expect to complete in the final quarter of 2020, to leverage our existing algorithms to create an 'IB Stroke' package."
The company said a "unique" feature of its imaging biometrics portfolio is its ability to accurately map and quantify blood flow in the brain.
"For example, IB's proven perfusion and diffusion maps will be used to generate the perfusion-diffusion mismatch which typically represents ischemic penumbra, or the area of viable tissue at risk. IB will leverage its proven ability of efficiently translating novel developments into routine clinical use, to create an automated and streamlined processing application for clinician's use," IQ-AI explained.
Chief Operating Officer David Smith added: "This initiative grew out of the solid progress we are making on our gadolinium free project and represents an area that is 30 times the size of that product opportunity. Further, it uses the diagnostic imaging techniques that are already in our FDA cleared IB suite of brain tumor focused products."
Shares in IQ-AI were down 3.0% in London on Thursday afternoon at 5.92 pence each.
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Iq-ai Ltd (IQAI)